Results 31 to 40 of about 3,638 (152)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting [PDF]

open access: yesOncoImmunology, 2013
Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy
Birklé, S.   +9 more
openaire   +3 more sources

Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog [PDF]

open access: yesJournal of Biological Chemistry, 2008
Multidrug resistance (MDR) via the ABC drug transporter (ABCB1), P-glycoprotein (P-gp/MDR1) overexpression, is a major obstacle in cancer chemotherapy. Many inhibitors reverse MDR but, like cyclosporin A (CsA), have significant toxicities. MDR1 is also a translocase that flips glucosylceramide inside the Golgi to enhance neutral glycosphingolipid (GSL)
María Fabiana, De Rosa   +5 more
openaire   +2 more sources

A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells

open access: yesCells, 2023
Aberrant glycosylation plays a crucial role in tumour progression and invasiveness. Tumour-associated carbohydrate antigens (TACAs) represent a valuable set of targets for immunotherapeutic approaches.
Jana Tomisch   +10 more
doaj   +1 more source

Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor

open access: yesFrontiers in Cellular and Infection Microbiology, 2020
Shiga toxin is the main virulence factor of non-invasive enterohemorrhagic Escherichia coli strains capable of causing hemolytic uremic syndrome. Our group has previously shown that the toxin can reach the kidney within microvesicles where it is taken up
Karl Johansson   +6 more
doaj   +1 more source

The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS

open access: yesMicroorganisms, 2021
In 90% of the cases, childhood hemolytic uremic syndrome (HUS) is caused by an infection with the Shiga toxin (Stx) producing E. coli bacteria (STEC-HUS).
Wouter J. C. Feitz   +6 more
doaj   +1 more source

Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit

open access: yesToxins, 2020
Shiga toxin (Stx)-stimulated blood cells shed extracellular vesicles (EVs) which can transfer the toxin to the kidneys and lead to hemolytic uremic syndrome.
Annie Willysson   +8 more
doaj   +1 more source

Enzymatic Glyco-Modification of Synthetic Membrane Systems

open access: yesBiomolecules, 2023
The present report assesses the capability of a soluble glycosyltransferase to modify glycolipids organized in two synthetic membrane systems that are attractive models to mimic cell membranes: giant unilamellar vesicles (GUVs) and supported lipid ...
Dylan Jabeguero   +8 more
doaj   +1 more source

The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer [PDF]

open access: yesProceedings of the National Academy of Sciences, 2005
The most devastating aspect of cancer is the emergence of metastases. Thus, identification of potentially metastatic cells among a tumor cell population and the underlying molecular changes that switch cells to a metastatic state are among the most important issues in cancer biology.
Kovbasnjuk, Olga   +7 more
openaire   +2 more sources

Determination of globotriaosylceramide in plasma and urine by mass spectrometry [PDF]

open access: yescclm, 2009
Abstract Background: Fabry disease is an X-chromosomally inherited lysosomal storage disorder leading to accumulation of glycosphingolipids, mainly globotriaosylceramide (ceramide-trihexoside, Gb3). Concentrations of Gb3 in plasma and urine have been used to diagnose Fabry disease and to monitor enzyme replacement ...
Krüger, Ralf   +6 more
openaire   +3 more sources

Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model

open access: yesJournal of Lipid Research, 2020
Fabry disease is caused by deficient activity of α-galactosidase A, an enzyme that hydrolyzes the terminal α-galactosyl moieties from glycolipids and glycoproteins, and subsequent accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3 ...
Siamak Jabbarzadeh-Tabrizi   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy